JPS63130593A - Pyrazolone derivative - Google Patents
Pyrazolone derivativeInfo
- Publication number
- JPS63130593A JPS63130593A JP27736486A JP27736486A JPS63130593A JP S63130593 A JPS63130593 A JP S63130593A JP 27736486 A JP27736486 A JP 27736486A JP 27736486 A JP27736486 A JP 27736486A JP S63130593 A JPS63130593 A JP S63130593A
- Authority
- JP
- Japan
- Prior art keywords
- group
- pyridyl
- pyrazolin
- methyl
- pyrazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 title claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- 125000002541 furyl group Chemical group 0.000 claims abstract description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract description 4
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- -1 (substituted) phenyl Chemical group 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000003836 peripheral circulation Effects 0.000 abstract description 4
- 208000019622 heart disease Diseases 0.000 abstract description 3
- 208000023589 ischemic disease Diseases 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 150000004725 beta keto acid derivatives Chemical class 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- 208000018152 Cerebral disease Diseases 0.000 abstract 1
- 150000002429 hydrazines Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 3
- 229960004135 idebenone Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960001844 tubocurarine Drugs 0.000 description 2
- SDOFMBGMRVAJNF-VANKVMQKSA-N (2s,3s,4s,5r)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO SDOFMBGMRVAJNF-VANKVMQKSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- OCYJXSUPZMNXEN-UHFFFAOYSA-N 2-amino-1-(4-nitrophenyl)propane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=C([N+]([O-])=O)C=C1 OCYJXSUPZMNXEN-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QYSOMFUUWROROT-UHFFFAOYSA-N 4-pyridin-2-ylbutan-1-ol Chemical compound OCCCCC1=CC=CC=N1 QYSOMFUUWROROT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 210000003735 pulvinar Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、諸種虚血性疾患並びにそれに伴う諸種脳疾患
、心疾患及び末梢循環障害の予防・治療剤として有用な
過酸化脂質生成抑制作用を有するピラゾロン誘導体に関
するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention has an inhibitory effect on lipid peroxide production, which is useful as a preventive/therapeutic agent for various ischemic diseases and accompanying various brain diseases, heart diseases, and peripheral circulation disorders. The present invention relates to pyrazolone derivatives having the following properties.
脳、心慶又は末梢における循環障害疾患において、虚血
(組織に血液が供給されない状態)Kより、細胞膜から
遊離されたアラキドン酸を始めとする不飽和脂肪酸に対
し、その周辺組織において生じた活性酸素種(oF1’
ラジカルスーパーオキサイド等)が作用して過酸化
脂質が生成する。このような変化は虚血中のみならず、
虚血再開通抜の血液を介する再酸素化により更に加速度
的に進展し、不飽和脂防酸に富む生体膜細胞の傷害、周
辺組織の破壊、血管内皮の破壊、血管管線又は浮腫等を
引き起こし、これら一連の反応の悪循環により病態が進
展することが知られている(「脳虚血と細胞障害」浅野
米雄編集 にゆ−ろん社、/り10; 「脳虚血とフリ
ーラジカル」浅野孝雄編集 にゆ−ろん社、/ 9e3
)。Activity that occurs in surrounding tissues of unsaturated fatty acids, including arachidonic acid, released from cell membranes due to ischemia (a condition in which blood is not supplied to tissues) in the brain, heart, or peripheral circulation disorders. Oxygen species (oF1'
Radical superoxide, etc.) act to generate lipid peroxide. These changes occur not only during ischemia, but also during
Reoxygenation via the blood after ischemia recanalization further accelerates the process, causing damage to biomembrane cells rich in unsaturated fat-protecting acids, destruction of surrounding tissues, destruction of vascular endothelium, vascular ducts, and edema. It is known that the pathological condition progresses due to the vicious cycle of these series of reactions ("Cerebral Ischemia and Cell Damage", edited by Yoneo Asano, Niyuronsha, / 10; "Cerebral Ischemia and Free Radicals", Asano Edited by Takao Niyuronsha, / 9e3
).
従って、活性酸素種による過酸化脂質生成を抑制すれば
、組織の破壊、血管内皮の破壊、血管ツ縮、浮腫等を防
ぐことが可能となシ、従来の血流を増加することによシ
循環改善をする薬物と全く異なり、疾患の原因に対して
作用する新しいタイプの循環障害予防・治療剤となる。Therefore, by suppressing the production of lipid peroxide caused by reactive oxygen species, it is possible to prevent tissue destruction, destruction of vascular endothelium, vasoconstriction, edema, etc.; Completely different from drugs that improve circulation, this is a new type of circulatory disorder prevention and treatment agent that acts on the cause of the disease.
特に近年、梗塞部において血流を増加することの有効性
が疑問視され、急性期脳血管障害ではむしろ逆効果とさ
え言われており、このような薬剤は更に重要性を増して
きている。Particularly in recent years, the effectiveness of increasing blood flow in the infarcted area has been questioned, and it has even been said to have the opposite effect in acute cerebrovascular disorders, and such drugs have become even more important.
活性酸素種による脂質過酸化を抑制する薬剤としては、
ビタミンE1
次式:
で示されるイデベノン(バイオケミカル・アンド・バイ
オフィジカル奉リサーチ・コミュニケーションズ(Bi
ochemical and Bioph7sical
Research Copmunications )
/2s 、 1OIA&(/?!弘);武田研究所
報!4! 、 30 (/9d’j))及び
次式:
で示されるニジフェノン(ジャーナル・オプ・* 二:
L −ロケミスドリー(ffournal of Ne
uro −chemistry) 37 、9j4c
(/りr/))が知られている。Drugs that suppress lipid peroxidation caused by reactive oxygen species include:
Vitamin E1 Idebenone (Biochemical and Biophysical Research Communications (Bi
chemical and bioph7sical
Research Communications)
/2s, 1OIA&(/?!Hiroshi); Takeda Institute News! 4! , 30 (/9d'j)) and the following formula: Nidiphenone (Journal Op *2):
L-Lochemistry (ffournal of Ne
uro-chemistry) 37, 9j4c
(/rir/)) is known.
しかしながら、ビタミンEは作用が不充分であ)、イデ
ベノン及びニジフェノンは合成経路等
が長く、またイデベノンは水への可溶化困難々ため注射
製剤化に問題が考えられ、ニジフェノンは中枢神経系の
抑制作用が強い(医薬品研究/l 、 / (/り/j
))という欠点を有する。However, the effects of vitamin E are insufficient), idebenone and nidiphenone have long synthesis routes, and idebenone is difficult to solubilize in water, so there are problems in making an injection formulation, and nidiphenone suppresses the central nervous system. Strong effect (Pharmaceutical research/l, / (/ri/j
)).
ピラゾロン誘導体としては、種々のものが知られている
。Various pyrazolone derivatives are known.
特公昭φj−/θ/≠!号公報、特公昭弘S −コに7
3乙号公報には下記式A
(式中R1は水素原子又はメチル基、R,は水素原子又
は置換基を表わす。)
で示される3−ピリジルピラゾリン−!−オン誘導体の
鎮痛剤、鎮痙剤としての用途が、Diss、Pharm
、PharmacOl、 / J’ (すJ 4(!
−! 0(/りtぶ)には、下記式B
で示される化合物の消炎剤としての用途が記載されてい
るが、活性酸素株による脂質過酸化を抑制する作用に関
する記載はない。Special public φj−/θ/≠! Publication No. 7, Special Publication Akihiro S-Co.
Publication No. 3 Otsu describes 3-pyridylpyrazoline-! represented by the following formula A (wherein R1 represents a hydrogen atom or a methyl group, and R represents a hydrogen atom or a substituent). The use of -one derivatives as analgesics and antispasmodics has been reported by Diss, Pharm.
,PharmacOl,/J' (suJ 4(!
-! 0 (/ritbu) describes the use of the compound represented by the following formula B as an anti-inflammatory agent, but there is no description regarding the effect of suppressing lipid peroxidation caused by active oxygen species.
Pubs、 1nst、 quim、 ”Alonso
Barba” (Madrid)上、Jlo−/s(
/りsO)及びケミカル アプストラクツ(Chemi
cal Abstracts ) vow、 弘t 。Pubs, 1nst, quim, “Alonso
Barba” (Madrid), Jlo-/s (
/ri sO) and Chemical Apstracts (Chemi
cal Abstracts) vow, Hirot.
7072(/りjコ)には下記式C
で示される化合物の植物ホルモン作用に関する記載があ
るが、薬理作用に関する記載はない。7072 (/rijco) has a description regarding the plant hormone action of the compound represented by the following formula C, but there is no description regarding the pharmacological action.
そこで、本発明者等は、活性酸素種による脂質過酸化を
抑制する作用を有する薬剤として有用な新規なピラゾロ
ン誘導体を提供することを目的として鋭意研究を重ねた
結果、
一般式(1)
(式中、R1はシクロアルキル基、置換基を有していて
もよいフェニル基またはピリジル基を表わし、R2は水
素原子またはアルキル基を表わし Haはピリジル基、
イミダゾリル基壇たけ7ラニル基を表わし、nはOまた
はlを表わす。Therefore, the present inventors conducted intensive research with the aim of providing a new pyrazolone derivative useful as a drug having the effect of inhibiting lipid peroxidation caused by reactive oxygen species. where R1 represents a cycloalkyl group, a phenyl group or a pyridyl group which may have a substituent, R2 represents a hydrogen atom or an alkyl group, Ha is a pyridyl group,
The imidazolyl base represents a seven-ranyl group, and n represents O or l.
但し、nがOでR3がピリジル基のとき R2はアルキ
ル基を表わし、nが0でR3がフラニル基、 のとき
、R1は置換フェニル基を表わす。)で表わされるピラ
ゾロン誘導体が強力な脂質過酸化抑制作用を有し、実際
の病態に近い脳虚血再開通状態の動物モデルにおいて、
脳波の回復等の保護作用を有することを見出し、本発明
を完成するに至った。However, when n is O and R3 is a pyridyl group, R2 represents an alkyl group, and when n is 0 and R3 is a furanyl group, R1 represents a substituted phenyl group. ) The pyrazolone derivative represented by ) has a strong lipid peroxidation inhibitory effect, and in an animal model of cerebral ischemia recanalization that is close to the actual pathology,
They discovered that it has protective effects such as recovery of brain waves, and completed the present invention.
本発明の化合物は、下記一般式(1′)で表わされるケ
ト型及び/又は一般式(I“)で表わされるエノール型
のピラゾロン誘導体である。The compound of the present invention is a keto-type pyrazolone derivative represented by the following general formula (1') and/or an enol-type pyrazolone derivative represented by the general formula (I'').
式中、RIH,シクロペンチル基、シクロヘキシル基、
シクロヘプチル基等の炭素数j〜7のシクロアルキル基
;置換基を有していてもよいフェニル基;またはピリジ
ル基を表わす。In the formula, RIH, cyclopentyl group, cyclohexyl group,
It represents a cycloalkyl group having j to 7 carbon atoms such as a cycloheptyl group; a phenyl group which may have a substituent; or a pyridyl group.
フェニル基の置換基としては、メチル基、エチル基、プ
ロピル基、イソプロピル基、ブチル基、イソブチル基、
Bf3C−ブチル基、tart−ブチル基、ペンチル基
等の炭素数/〜!のアルキル基;メトキシ基、エトキシ
基、プロポキシ基、イソプロポキシ基、ブトキシ基、ペ
ンチルオキシ基等の炭素数/〜!のアルコキシ基;塩素
原子等のハロゲン原子;メトキシカルボニル基、エトキ
シカルボニル基、プロポキシカルボニル基、ブトキシカ
ルボニル基等の総炭素数2〜!のアルコキシカルボニル
基;カルボキシル基;総炭素数3〜乙のアルコキシカル
ボニルメチル基等のアルコキシカルボニルアルキh基;
fy ルボキシメチル基等のカルボキシアルキル基;
メチルメルカプト基、エチルメルカプト基、プロピルメ
ルカプト基等の炭素数/〜3のアルキルメルカプト基;
トリフルオロメチル基;ヒドロキシル基等が挙げられる
。Substituents for phenyl group include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group,
Number of carbon atoms in Bf3C-butyl group, tart-butyl group, pentyl group, etc./~! Alkyl group; carbon number of methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, pentyloxy group, etc./~! Alkoxy group; halogen atom such as chlorine atom; total number of carbon atoms such as methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, butoxycarbonyl group is 2~! an alkoxycarbonyl group; a carboxyl group; an alkoxycarbonylalkyl group such as an alkoxycarbonylmethyl group having a total carbon number of 3 to O;
fy carboxyalkyl group such as carboxymethyl group;
an alkylmercapto group having a carbon number of ~3, such as a methylmercapto group, an ethylmercapto group, and a propylmercapto group;
Examples include trifluoromethyl group; hydroxyl group.
R2は、水素原子または炭素数/〜!のアルキル基を表
わす。R2 is a hydrogen atom or the number of carbon atoms/~! represents an alkyl group.
R1は、ピリジル基、イミダゾリル基または7ラニル基
を表わす。R1 represents a pyridyl group, an imidazolyl group or a 7-ranyl group.
nは0または/の数を表わす。n represents 0 or the number of /.
本発明の化合物においては、R1としてはシクロヘキシ
ル基、フェニル基、弘−メチルフェニル基、参−エチル
フェニル基、弘−メトキシ基、≠−エトキシ基、≠−ク
ロロフェニル基が好ましく、R2としては水素原子、メ
チル基、エチル基、プロピル基が好ましく、R3として
はピリジル基、フラニル基が好ましい。又、特に%R1
がφ−メチルフェニル基又は弘−クロロフェニル基を表
わし、R2が水素原子、メチル基、エチル基又はプロピ
ル基を表わし、R3がピリジル基を表わす化合物が好ま
しい。In the compound of the present invention, R1 is preferably a cyclohexyl group, phenyl group, Hiro-methylphenyl group, ethylphenyl group, Hiro-methoxy group, ≠-ethoxy group, or ≠-chlorophenyl group, and R2 is a hydrogen atom. , methyl group, ethyl group, and propyl group are preferable, and as R3, pyridyl group and furanyl group are preferable. Also, especially %R1
is a φ-methylphenyl group or a Hiro-chlorophenyl group, R2 is a hydrogen atom, a methyl group, an ethyl group or a propyl group, and R3 is a pyridyl group.
かかる本発明のピラゾロン誘導体の具体例としては、例
えば、以下に示すような化合物が挙げられる。Specific examples of such pyrazolone derivatives of the present invention include the following compounds.
参−メチル−/−フェニル−j−(J−ピリジル)−コ
ービラゾリンーj−オン
参−メチル−/−(弘−メチルフェニル)−3−(3−
ピリジル)−2−ピラゾリン−5−オン
p−メチル−/−(J−メチルフェニル)−3−(3−
ピリジル)−2−ピラゾリン−!−オン
/−(μ−エチルフェニル)−膳−メチル−3−(3−
ピリジル)−λ−ピラゾリンー!−オン
≠−メチルー/−(弘−プロビルフェニル)−3−(3
−ピリジル)−ノービラゾリン−5−オン
/−(≠−ブチルフェニル)−≠−メチルー3−(3−
ピリジル)−2−ピラゾリン−!−オン
4’−メfルー/−(≠−ペンチルフェニル)−3−(
3−ピリジル)−コーピラゾリンー!−オン
/ −(J、4L−シメfルフェニル)−≠−メチルー
J−(J−ピリジル)−2−ピラゾリン−5−オン
/ −(J、弘、j−トリメチルフェニル)−μmメチ
ル−3−(3−ピリジル)−コーピラゾリンー!−オン
/−(弘−メトキクフェニル)−ターメチル−3−(3
−ピリジル)−2−ピラゾリン−5−オン
/−(j−メトキシフェニル)−≠−メチルー3−(3
−ピリジル)−2−ピラゾリン−!−オン
/−(μ−エトキシフェニル)−μmメチル−3−(3
−ピリジル)−2−ピラゾリン−5−オン
≠−メチルー/−(≠−プロポキシフェニル)−J−(
J−ピリジル)−ノーピラゾリン−5−オン
/−(≠−フトキシフェニル)−≠−メチルー3−(3
−ピリジル)−2−ピラゾリン−j−オン
/ −(J、44−ジメトキシフェニル)−μmメチル
−j−(J−ピリジル)−コービラゾリンー!−オン
i−(4cmクロロフェニル)−μmメチル−3−(3
−ピリジル)−2−ピラゾリン−j−オ1−(J−クロ
ロフェニル)−≠−メチルー3−(3−ピリジル)−2
−ピラゾリン−j−オン
l−(≠−フルオロフェニル)−μmメチル−3−(3
−ピリジル)−2−ピラゾリン−!−オン
/ −(j、4!−ジクロロフェニル)−−2メチル−
3−(J−ピリジル)−2−ピラン1ノンーj−オン
≠−メチルー/−(弘−メチルチオフェニル)−J−(
J−ピリジル)−2−ピラゾリン−!−オ/
/−(J−クロロ−μ−メチルフェニル)−弘−メチル
−3−(3−ピリジル)−2−ビラシーメチル−3−(
3−ピリジル)−一一ビラゾリンー!−オン
/−(4L−ヒドロキシフェニル)−ターメチル−J−
(J−ピリジル)−2−ピラゾリン−!−オン
/−(j、e−ジヒドロキシフェニル)−u−メチル−
3−(3−ピリジル)−2−ピラゾリン−j−オン
/−(<C−エトキシカルボニルフェニル)−3−(3
−ピリジル)−2−ピラゾリン−!−オン
≠−〔弘−メチル−3−(3−ピリジル)−s−オキン
ー2−ピラゾリン−7−イル)安息香酸
/−(44−エトキシカルボニルメチルフェニル)−参
−メチル−3−(3−ピリジル)−2−ピラゾリン−5
−オン
φ−〔≠−メチルー3−(3−ピリジル)−s−オキソ
ーコービラゾリン−/−イル〕フェニル酢酸
≠−メチルー/−(α−ナフチル)−J−(j−ビリジ
ル)−2−ピラゾリy−j−オン/−シクロペンチル−
弘−メチル−J−(j−ピリジル)−2−ピラゾリン−
5−オンノーシクロへフチルー≠−メチル−3−(J−
ピリジル)−コービラゾリンー5−オン/−シクロへキ
シル−≠−メチルーJ−(j−(3−ピリジル)−2−
ピラゾリン−!−オンμmメチルー3−(3−ピリシー
ル)−/−(2−ピリミジル)−2−ピラゾリン−j−
オン
弘−メチル−/−(3−ピリダジール)−3−(3−ピ
リジル)−2−ピラゾリン−j−オン/−(2−ベンゾ
チアゾリル)−≠−メチルー3−(3−ピリジル)−2
−ピラゾリン−5−オン
≠−メチルー/−フェニルー3−(2−ピリジル)−2
−ピラゾリン−j−オン
≠−メチルー/−フェニルー3−(弘−ピリジル)−コ
ービラゾリンー5−オン
V−メチル−/−(2−ピリシール)−3−(3−ピリ
ジル)−2−ピラゾリン−j−オン弘−メチル−/−(
弘−ビリジクル)−3−(3−ピリジル)−コービラゾ
リンーj−オン弘−エチル−/−フェニル−j−(3−
ヒIJ シル)−λ−ビラシリンー!−オン
弘−エチル−/−(4cmメチルフェニル)−3−(3
−ピリジル)−λ−ピラゾリンーj−オン
弘−エチル−/−(≠−エチルフェニル)−3−(3−
ピリジル)−2−ピラゾリン−j−オン
/−(≠−フチルフェニル)−ルーエチル−3−(3−
ピリジル)−2−ピラゾリン−j−オン
≠−エチルー/ −(J、≠−ジメチルフェニル)−3
−(3−ピリジル)−2−ピラゾリン−!−オン≠−エ
チルー/−(≠−メトキシフェニル)−3−(3−ピリ
ジル)−コービラゾリンーj−オン
/−(44−エトキシフェニル)−φ−エチルー3−(
3−ピリジル)−2−ピラゾリン−5−オン
/−(≠−クロロフェニル)−≠−エチルー3−(3−
ピリジル)−2−ピラゾリン−!−オン
/−シクロヘキシル−弘−エチル−j−(j−ピリジル
)−2−ピラゾリン−5−オン≠−エチル−/−(,2
−ピリジ・ル)−3−(3−ピリジル)−λ−ピラゾリ
ンー5−オン/−フェニル−弘−プロビル−J−(j−
ピリジル)−2−ピラゾリン−j−オン
/−(≠−メチルフェニル)−ループロビル−3−(3
−ピリジル)−コービラゾリンー5−オン
/−(4c−エチルフェニル)−φ−プロピルー3−(
3−ピリジル)−λ−ピラゾリンーj−オン
/−(+−メトキシフェニル)−≠−プロピルーj−(
j−ピリジル)−2−ピラゾリン−!−オン
/−(≠−エトキシフェニル)−契一プロビル−j−(
j−ピリジル)−コーピラゾリンー!−オン
/−(≠−クロロフェニル)−ループロビルー3−(3
−ピリジル)−2−ピラゾリン−5−オン
)し
/−シクロヘキシメー弘−プロピル−3−(J−ピリジ
ル)−一一ビラゾリンーj−オンa−フチルー/−フェ
ニル−j−(J−ヒIJ シル)−コービラゾリンーj
−オン
/−フェニル−J −(J −?’ I7 シルメチル
)−一一ビラゾリンーj−オン
/−(4!−メチルフェニル)−J−(j−ピリジルメ
チル)−2−ピラゾリン−5−オン/−(3−メチルフ
ェニル)−J−(j−ピリジルメチル)−2−ビラゾリ
ンー5−オン/−(2−メチルフェニル)−J−(J−
ピリジルメチル)−2−ビラゾリンー5−オン/−(4
c−エチルフェニル)−j−(j−ピリジルメチル)−
,2−ピラゾリン−!−オン/−(≠−プロピルフェニ
ル)−j−(J−ピリジルメチル)−2−ピラゾリン−
j−オン/−(≠−ブチルフェニル)−j−(J−ピリ
ジルメチル)−コービラゾリンーj−オン/ −(j、
弘−ジメチルフェニル)−3−(3゜ピリジルメチル)
−2−ピラゾリン−j−オン/−(4g−メトキシフェ
ニル)−j−(j−ピリジルメチル)−コーピラゾリン
ー!−オン/−(3−メトキシフェニル)−J−CJ−
ピリジルメチル)−コーピラゾリンー!−オン/−(4
c−エトキシフェニル)−j−(J−ピリジルメチル)
−2−ピラゾリン−j−オン/−(≠−ブトキシフェニ
ル)−J−(j−ピリジルメチル)−2−ピラゾリン−
!−オン/−(J、弘−ジメトキシフェニル)−j−(
j−ピリジルメチル)−2−ピラゾリン−j−オン
/−(4cmクロロフェニル)−3−(J−ピリジルメ
チル)−2−ピラゾリン−!−オン/−(≠−フルオロ
フェニル)−j−(j−ビー(3−ピリジルメチル)−
2−ピラゾリン−!−オン
/−(≠−メチルチオフェニル)−j−(j−ピリジル
メチル)−2−ピラゾリン−!−オン弘−(J−(j−
ピリジルメチル)−5−オキソーコービラゾリンー/−
イル〕安息香酸/−(弘−ヒドロキシフェニル)−J−
(J−ピリジルメチル)−2−ピラゾリン−5−オン/
−(α−ナフチル)−J−(3−ピリジルメチル)−2
−ピラゾリン−!−オン
/−シクロヘキシルーJ−(J−ピリジルメチル)−コ
ービラゾリンーj−オン
/−(2−ピリジニル)−J−(j−ピリジルメチル)
−2−ピラゾリン−!−オン
/−フェニルーJ −(2−ピリジルメチル)−一一ビ
ラゾリンー5−オン
/−(4cmメチルフェニル)−3−(,2−ピリジル
メチル)−コービラゾリンー5−オン/−フェニル−3
−(≠−ヒリシルメチル)−2−ピラゾリン−5−オン
3−(2−フラニル)−/−(≠−メチルフェニル)−
2−ピラゾリン−5−オン
3−(2−フラニル)−/−(3−メチルフェニル)−
2−ピラゾリン−j−オン
3−(2−フラニル)−/−(,2−メチル7エ二ル)
−コービラゾリンーj−オン
/−(≠−エチルフェニル)−j−(2−フラニル)−
2−ピラゾリン−j−オン
/−(弘−ブチルフェニル)−J−(2−フラニル)−
2−ピラゾリン−j−オン
3−(2−フラニル)−/−(J$参−ジメチルフェニ
ル)−s−ピラゾリン−!−オン3−(2−フラニル)
−/−(≠−メトキシフェニル) −、z−ピラゾリン
−!−オン3−(2−フラニル)−/−(j−メトキシ
フェニル)−2−ピラゾリン−j−オン
/−(44−エトキシフェニル)−j−(2−フラニル
)−2−ピラゾリン−j−オン
/−(亭−ブトキシフェニル) −j −(J −7ラ
ニル)−2−ピラゾリン−!−オン
3−(2−フラニル)−/−(J、弘−ジメトキシフェ
ニル)−コーピラゾリンーj−オン/−(≠−クロロフ
ェニル)−J−(コーフラニル)−2−ピラゾリン−!
−オン
/−(4!−フルオロフェニル)−J−(,2−フラニ
ル)−2−ピラゾリン−!−オン
3−(2−フラニル)−/−(弘−メチルチオフェニル
)−コービラゾリンーj−オン/ −(a −) リフ
ルオロメチルフェニル)−3−(,2−フラニル)−コ
ーピラゾリンーj−オン
3−(2−フラニル)−/−(弘−ヒドロキシフェニル
)−2−ピラゾリン−j−オン/−シクロヘキシル−j
−(2−フラニル)−コービラゾリンー5−オン
3−(2−フラニル)−/−(α−ナフチル)−2−ピ
ラゾリン−j−オン
3−(コーフラニル)−/−(J−ピリジル)−2−ピ
ラゾリン−5−オン
S−(/−イミダゾリル)−/−フェニル−2−ピラゾ
リン−!−オン
3−(/−イミダゾリル)−/−(≠−メチルフェニル
)−コーピラゾリンーj−オン3−(/−イミダゾリル
)−/−(j−メチルフェニル)−2−ピラゾリン−j
−オン/−(弘−エチルフェニル)−j−(/−イミダ
ゾリル)−コービラズリンーj−オン/−(4!−ブチ
ルフェニル)−J−(/−イミダゾリル)−コーピラゾ
リンー!−オン3−(/−イミダゾリル)−/−(J、
弘−ジメチルフェニル)−コービラゾリンーj−オン3
−(/−イミダゾリル)−ノー(44−メトヤシフェニ
ル)−コービラゾリ/−j−オン3−(/−イミダゾリ
ル)−/−(J−メトヤシフェニル)−λ−ピラゾリン
ー5−オン/−(弘−エトキシフェニル)−J−(/−
イミダゾリル)−λ−ピラゾリンー5−オン/−(≠−
ブトキシフェニル)−J−(/−イミダゾリル)−二一
ビラゾリン−5−オン/−(ILL−クロロフェニル)
−3−(/−イミダゾリル)−2−ピラゾリン−j−オ
ン/−(lLt−フルオロフェニル)−J−(/−イー
イミダゾリル)−ニーピラゾリンー5−オン3−(/−
イミダゾリル)−/−(α−ナフチル)−2−ピラゾリ
ン−5−オン
/−シクロへ参シル−J−(/−イミダゾリル)−2−
ピラゾリン−j−オン
3−(/−イミダゾリル)−/−(λ−ピリジル)−2
−ピラゾリン−j−オン
等
本発明の上記ピラゾロン誘導体を薬剤として使用する場
合は、薬剤として許容される塩として使用してもよい。3-methyl-/-phenyl-j-(J-pyridyl)-cobylazolin-j-on 3-methyl-/-(Hiro-methylphenyl)-3-(3-
pyridyl)-2-pyrazolin-5-one p-methyl-/-(J-methylphenyl)-3-(3-
pyridyl)-2-pyrazoline-! -one/-(μ-ethylphenyl)-zen-methyl-3-(3-
pyridyl)-λ-pyrazoline! -one≠-methyl-/-(Hiro-propylphenyl)-3-(3
-pyridyl)-novirazolin-5-one/-(≠-butylphenyl)-≠-methyl-3-(3-
pyridyl)-2-pyrazoline-! -on4'-mef/-(≠-pentylphenyl)-3-(
3-pyridyl)-copyrazoline! -one/-(J, 4L-shimefruphenyl)-≠-methyl-J-(J-pyridyl)-2-pyrazolin-5-one/-(J, Hiro, j-trimethylphenyl)-μm methyl-3- (3-pyridyl)-copyrazoline! -one/-(Hiro-methoxyphenyl)-termethyl-3-(3
-pyridyl)-2-pyrazolin-5-one/-(j-methoxyphenyl)-≠-methyl-3-(3
-pyridyl)-2-pyrazoline-! -one/-(μ-ethoxyphenyl)-μmmethyl-3-(3
-pyridyl)-2-pyrazolin-5-one≠-methyl/-(≠-propoxyphenyl)-J-(
J-pyridyl)-nopyrazolin-5-one/-(≠-phthoxyphenyl)-≠-methyl-3-(3
-pyridyl)-2-pyrazolin-j-one/-(J,44-dimethoxyphenyl)-μmmethyl-j-(J-pyridyl)-kovirazoline-! -one i-(4cm chlorophenyl)-μm methyl-3-(3
-pyridyl)-2-pyrazoline-j-o1-(J-chlorophenyl)-≠-methyl-3-(3-pyridyl)-2
-pyrazolin-j-one l-(≠-fluorophenyl)-μm methyl-3-(3
-pyridyl)-2-pyrazoline-! -one/-(j,4!-dichlorophenyl)--2methyl-
3-(J-pyridyl)-2-pyran 1 non-j-one≠-methyl/-(Hiro-methylthiophenyl)-J-(
J-pyridyl)-2-pyrazoline-! -o/ /-(J-chloro-μ-methylphenyl)-Hiro-methyl-3-(3-pyridyl)-2-bilacymethyl-3-(
3-pyridyl)-11 birazoline! -one/-(4L-hydroxyphenyl)-termethyl-J-
(J-pyridyl)-2-pyrazoline-! -one/-(j,e-dihydroxyphenyl)-u-methyl-
3-(3-pyridyl)-2-pyrazolin-j-one/-(<C-ethoxycarbonylphenyl)-3-(3
-pyridyl)-2-pyrazoline-! -one≠-[Hiro-methyl-3-(3-pyridyl)-s-oquine-2-pyrazolin-7-yl)benzoic acid/-(44-ethoxycarbonylmethylphenyl)-3-methyl-3-(3- pyridyl)-2-pyrazoline-5
-oneφ-[≠-methyl-3-(3-pyridyl)-s-oxocorbyrazolin-/-yl]phenylacetic acid≠-methyl-/-(α-naphthyl)-J-(j-pyridyl)-2- Pyrazoliy-j-one/-cyclopentyl-
Hiro-Methyl-J-(j-pyridyl)-2-pyrazoline-
5-onocyclohephthyl≠-methyl-3-(J-
pyridyl)-Corbylazolin-5-one/-cyclohexyl-≠-methyl-J-(j-(3-pyridyl)-2-
Pyrazoline! -one μm methyl-3-(3-pyrisyl)-/-(2-pyrimidyl)-2-pyrazoline-j-
Onhiro-Methyl-/-(3-pyridazyl)-3-(3-pyridyl)-2-pyrazolin-j-one/-(2-benzothiazolyl)-≠-methyl-3-(3-pyridyl)-2
-pyrazolin-5-one≠-methyl-/-phenyl-3-(2-pyridyl)-2
-Pyrazolin-j-one ≠ -methyl-/-phenyl-3-(Hiro-pyridyl)-Kobirazolin-5-one V-methyl-/-(2-pyrisyl)-3-(3-pyridyl)-2-pyrazoline-j- Onghiro-Methyl-/-(
Hiro-Biridicle)-3-(3-pyridyl)-Kobirazolin-j-one Hiro-ethyl-/-phenyl-j-(3-
HiIJ Sil)-λ-Biracilin! -onhiro-ethyl-/-(4cm methylphenyl)-3-(3
-pyridyl)-λ-pyrazoline-j-one Hiro-ethyl-/-(≠-ethylphenyl)-3-(3-
pyridyl)-2-pyrazolin-j-one/-(≠-phthylphenyl)-ruethyl-3-(3-
pyridyl)-2-pyrazolin-j-one≠-ethyl/-(J,≠-dimethylphenyl)-3
-(3-pyridyl)-2-pyrazoline-! -one≠-ethyl/-(≠-methoxyphenyl)-3-(3-pyridyl)-kobyrazolin-j-one/-(44-ethoxyphenyl)-φ-ethyl-3-(
3-pyridyl)-2-pyrazolin-5-one/-(≠-chlorophenyl)-≠-ethyl-3-(3-
pyridyl)-2-pyrazoline-! -one/-cyclohexyl-hiro-ethyl-j-(j-pyridyl)-2-pyrazolin-5-one≠-ethyl-/-(,2
-pyridyl)-3-(3-pyridyl)-λ-pyrazolin-5-one/-phenyl-Hiro-provir-J-(j-
pyridyl)-2-pyrazolin-j-one/-(≠-methylphenyl)-luprovir-3-(3
-pyridyl)-kobilazolin-5-one/-(4c-ethylphenyl)-φ-propyl-3-(
3-pyridyl)-λ-pyrazolin-j-one/-(+-methoxyphenyl)-≠-propyl-j-(
j-pyridyl)-2-pyrazoline-! -one/-(≠-ethoxyphenyl)-Kiichiprovir-j-(
j-pyridyl)-copyrazoline! -one/-(≠-chlorophenyl)-luprovir-3-(3
-pyridyl)-2-pyrazolin-5-one)/-cyclohexyme-propyl-3-(J-pyridyl)-1-birazolin-j-one a-phthyl/-phenyl-j-(J-hyIJ sil )-Kobirazorin-j
-one/-phenyl-J -(J-?' I7 Cylmethyl)-1-birazolin-j-one/-(4!-methylphenyl)-J-(j-pyridylmethyl)-2-pyrazolin-5-one/ -(3-methylphenyl)-J-(j-pyridylmethyl)-2-birazolin-5-one/-(2-methylphenyl)-J-(J-
pyridylmethyl)-2-birazolin-5-one/-(4
c-ethylphenyl)-j-(j-pyridylmethyl)-
,2-pyrazoline-! -one/-(≠-propylphenyl)-j-(J-pyridylmethyl)-2-pyrazoline-
j-one/-(≠-butylphenyl)-j-(J-pyridylmethyl)-kobyrazolin-j-one/-(j,
Hiro-dimethylphenyl)-3-(3゜pyridylmethyl)
-2-pyrazolin-j-one/-(4g-methoxyphenyl)-j-(j-pyridylmethyl)-copyrazoline-! -one/-(3-methoxyphenyl)-J-CJ-
pyridylmethyl)-copyrazoline! -on/-(4
c-ethoxyphenyl)-j-(J-pyridylmethyl)
-2-pyrazoline-j-one/-(≠-butoxyphenyl)-J-(j-pyridylmethyl)-2-pyrazoline-
! -one/-(J, Hiro-dimethoxyphenyl)-j-(
j-pyridylmethyl)-2-pyrazolin-j-one/-(4cm chlorophenyl)-3-(J-pyridylmethyl)-2-pyrazoline-! -one/-(≠-fluorophenyl)-j-(j-bi(3-pyridylmethyl)-
2-Pyrazoline-! -one/-(≠-methylthiophenyl)-j-(j-pyridylmethyl)-2-pyrazoline-! -On Hong-(J-(j-
pyridylmethyl)-5-oxocorbylazoline-/-
yl]benzoic acid/-(Hiro-hydroxyphenyl)-J-
(J-pyridylmethyl)-2-pyrazolin-5-one/
-(α-naphthyl)-J-(3-pyridylmethyl)-2
-Pyrazoline-! -one/-cyclohexyl-J-(J-pyridylmethyl)-cobylazolin-j-one/-(2-pyridinyl)-J-(j-pyridylmethyl)
-2-pyrazoline-! -one/-phenyl-J -(2-pyridylmethyl)-1-birazolin-5-one/-(4cm methylphenyl)-3-(,2-pyridylmethyl)-covilazolin-5-one/-phenyl-3
-(≠-hyricylmethyl)-2-pyrazolin-5-one 3-(2-furanyl)-/-(≠-methylphenyl)-
2-pyrazolin-5-one 3-(2-furanyl)-/-(3-methylphenyl)-
2-pyrazolin-j-one 3-(2-furanyl)-/-(,2-methyl7enyl)
-Kobirazolin-j-one/-(≠-ethylphenyl)-j-(2-furanyl)-
2-pyrazolin-j-one/-(Hiro-butylphenyl)-J-(2-furanyl)-
2-pyrazoline-j-one 3-(2-furanyl)-/-(J$-dimethylphenyl)-s-pyrazoline-! -one 3-(2-furanyl)
-/-(≠-methoxyphenyl) -,z-pyrazoline-! -one 3-(2-furanyl)-/-(j-methoxyphenyl)-2-pyrazolin-j-one/-(44-ethoxyphenyl)-j-(2-furanyl)-2-pyrazolin-j-one /-(tei-butoxyphenyl)-j-(J-7ranyl)-2-pyrazoline-! -one 3-(2-furanyl)-/-(J, Hiro-dimethoxyphenyl)-copyrazoline-j-one/-(≠-chlorophenyl)-J-(cofuranyl)-2-pyrazoline-!
-one/-(4!-fluorophenyl)-J-(,2-furanyl)-2-pyrazoline-! -one 3-(2-furanyl)-/-(Hiro-methylthiophenyl)-copyrazolin-j-one/-(a-)lifluoromethylphenyl)-3-(,2-furanyl)-copyrazolin-j-one 3- (2-furanyl)-/-(Hiro-hydroxyphenyl)-2-pyrazolin-j-one/-cyclohexyl-j
-(2-furanyl)-covilazolin-5-one 3-(2-furanyl)-/-(α-naphthyl)-2-pyrazolin-j-one 3-(coufuranyl)-/-(J-pyridyl)-2- Pyrazolin-5-one S-(/-imidazolyl)-/-phenyl-2-pyrazoline-! -one 3-(/-imidazolyl)-/-(≠-methylphenyl)-copyrazoline-j-one 3-(/-imidazolyl)-/-(j-methylphenyl)-2-pyrazoline-j
-one/-(Hiro-ethylphenyl)-j-(/-imidazolyl)-copylazurin-j-one/-(4!-butylphenyl)-J-(/-imidazolyl)-copyrazoline-! -one 3-(/-imidazolyl)-/-(J,
Hiro-dimethylphenyl)-Kobirazolin-j-one 3
-(/-imidazolyl)-no(44-methoyaciphenyl)-cobylazoli/-j-one 3-(/-imidazolyl)-/-(J-methoyaciphenyl)-λ-pyrazolin-5-one/-(Hiro -ethoxyphenyl)-J-(/-
imidazolyl)-λ-pyrazolin-5-one/-(≠-
butoxyphenyl)-J-(/-imidazolyl)-21birazolin-5-one/-(ILL-chlorophenyl)
-3-(/-imidazolyl)-2-pyrazolin-j-one/-(lLt-fluorophenyl)-J-(/-imidazolyl)-neepyrazolin-5-one 3-(/-
imidazolyl)-/-(α-naphthyl)-2-pyrazolin-5-one/-cyclohexyl-J-(/-imidazolyl)-2-
Pyrazolin-j-one 3-(/-imidazolyl)-/-(λ-pyridyl)-2
When the above-mentioned pyrazolone derivatives of the present invention, such as -pyrazolin-j-one, are used as a drug, they may be used as a pharmaceutically acceptable salt.
かかる塩としては、塩酸、硫酸、臭化水素酸、リン酸等
の鉱酸との塩;メタンスルホン酸、p−トルエンスルホ
ン酸、ベンゼンスルホン酸、酢酸、グリコール酸、タル
ク1ン酸1¥レイン酸、フマル酸、シュウ酸、アスコル
ビン酸、クエン酸、サリチル酸、ニコチン酸、酒石酸等
の有機酸との塩;ナトIJウム、カリウム等のアルカリ
金属との塩;マグネシウム、カルシウム等のアルカリ土
類金属との塩;アンモニア、トリス(ヒドロキシメチル
)アミノメタン、N、N−ビス(ヒドロキシエチル)ピ
ペラジン、コーアミノーλ−メチルー/−プロパツール
、エタノールアミン、N−メチルグルカミン、L−グル
カミン等のアミンとの塩が挙けられる。Examples of such salts include salts with mineral acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, and phosphoric acid; methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, acetic acid, glycolic acid, and talc monophosphate. acids, salts with organic acids such as fumaric acid, oxalic acid, ascorbic acid, citric acid, salicylic acid, nicotinic acid, tartaric acid, etc.; salts with alkali metals such as sodium, potassium, etc.; alkaline earth metals such as magnesium, calcium, etc. with amines such as ammonia, tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, co-amino-λ-methyl/-propatur, ethanolamine, N-methylglucamine, L-glucamine, etc. Examples include salt.
本発明に用いる化合物は、合目的な任意の方法で合成す
ることができるが、好ましい方法の7例を次に示す。The compound used in the present invention can be synthesized by any suitable method, and seven preferred methods are shown below.
1m
(It) (III) (1)(
式中、p、1%R1、R3及びnは前記と同義であり、
R4は炭素数/〜!のアルキル基を表わす。)
即ち、式(n)で示されるβ−ケト酸誘導体と式(II
I)で示されるヒドラジン銹導体を、例えばメタノール
、エタノール等のアルコール類若しくはベンゼン、トル
エン等芳香族類のような溶媒の存在下又は無溶媒で、必
要に応じて、炭酸カリウム、ナトリウム、エトキシド、
カリウム−1−ブトキシド、水酸化ナトリウム、水酸化
カリウム、酢酸ナトリウム等の塩基;塩酸、硫酸、臭化
水素酸郷の鉱酸;酢酸、パラトルエンスルホン酸等の有
機酸等の触媒の存在下、10〜SOO℃の温度で反応さ
せることにより、化合物(りを得ることができる。1m (It) (III) (1)(
In the formula, p, 1% R1, R3 and n are as defined above,
R4 is the number of carbon atoms/~! represents an alkyl group. ) That is, the β-keto acid derivative represented by formula (n) and the formula (II
The hydrazine conductor represented by I) is optionally treated with potassium carbonate, sodium, ethoxide,
In the presence of catalysts such as bases such as potassium-1-butoxide, sodium hydroxide, potassium hydroxide, sodium acetate; mineral acids such as hydrochloric acid, sulfuric acid, and hydrobromic acid; organic acids such as acetic acid and para-toluenesulfonic acid; The compound (R) can be obtained by reacting at a temperature of 10 to SOO°C.
寸た R1のフェニル基の置換基によっては次に示す様
にして目的物を合成することができる。Depending on the substituent of the phenyl group of R1, the desired product can be synthesized as shown below.
(式中、R1、R2、R3及びnは前記と同義であり、
P5及びR6はそれぞれ炭素数7〜5のアルキル基を表
わし、mは0又は/の数を表わす。)
又、該置換基が水酸基である目的化合物(1)は、例え
ば適当なアルコキシ基を臭化水素酸又はルイス酸等で分
解することにより得ること7!l=できる。更に核置換
基がカルボキシ基あるいはカルボキクメチル基の場合は
例えばアルコキシカルボニル基、アルコキシカルボニル
メチル某ヲ酸あるいはアルカリ等通常の条件によシ加水
分解することにより目的化合物(1)を得ることが出来
る。(In the formula, R1, R2, R3 and n have the same meanings as above,
P5 and R6 each represent an alkyl group having 7 to 5 carbon atoms, and m represents 0 or the number of /. ) Furthermore, the target compound (1) in which the substituent is a hydroxyl group can be obtained, for example, by decomposing a suitable alkoxy group with hydrobromic acid, Lewis acid, etc. 7! l=I can do it. Furthermore, when the nuclear substituent is a carboxy group or a carboxymethyl group, the target compound (1) can be obtained by hydrolysis under usual conditions such as an alkoxycarbonyl group, an alkoxycarbonylmethyl acid or an alkali. .
化合物(1)を臨床に応用するに際し、仔口的に用いる
場合は、成人に対し7回化合物(1)として7〜100
mqを787〜3回投与するのが好ましく、静脈注射の
場合は、成人に対し7回化合物(1)として0.07〜
/θη夕を7日2〜5回投与又はこれらの用量を点滴持
続注入するのが好ましく、また、直鴨内投与の場合は、
1回化合物(1)として、7〜100■を7日/〜3回
投与するのが好ましい。甘た、以上の投与量は、年齢、
病態、症状により適宜増減することが更に好ましい。When applying compound (1) clinically, when using it parenterally, administer 7 to 100 doses of compound (1) to adults 7 times.
It is preferable to administer mq 787 to 3 times, and in the case of intravenous injection, administer compound (1) 0.07 to 7 times to adults.
It is preferable to administer /θη 2 to 5 times a day or to continuously infuse these doses by intravenous drip, and in the case of direct intravenous administration,
It is preferable to administer 7 to 100 μl of compound (1) once every 7 days/~3 times. Sweet, higher dosage, age,
It is more preferable to increase or decrease the amount as appropriate depending on the pathological condition and symptoms.
また、経口又は直腸内投与の場合は、徐放化製剤として
用いてもよい。In addition, in the case of oral or rectal administration, it may be used as a sustained release preparation.
製剤化に際しては、化合物(1)又はその薬学的に許容
される塩の一種又は二種以上を、通常用いられる製薬用
担体、賦形剤その他の添加物しど
を含む組成物として使用するのふつうである。When formulating a formulation, compound (1) or one or more of its pharmaceutically acceptable salts may be used as a composition containing commonly used pharmaceutical carriers, excipients, and other additives. It's normal.
医薬担体は固体でも液体でもよく、固体担体0例として
は乳糖、白陶土(カオリン)、ショ糖・結晶セルロース
、コーンスターチ、タルク、寒天、イクチン、アカシア
、ステアリン酸、ステアリン酸マグネシウム、レシチン
、塩化ナトリウム等が挙げられる。Pharmaceutical carriers may be solid or liquid; examples of solid carriers include lactose, china clay (kaolin), sucrose/crystalline cellulose, cornstarch, talc, agar, ictin, acacia, stearic acid, magnesium stearate, lecithin, and sodium chloride. etc.
液状の担体の例としては、シロップ、グリセリン、落花
生油、ポリビニルピロリドン、オリーフ湯、エタノール
、ベンジルアルコール、プロピレングリコール、水等が
挙げられる。Examples of liquid carriers include syrup, glycerin, peanut oil, polyvinylpyrrolidone, olive hot water, ethanol, benzyl alcohol, propylene glycol, water, and the like.
種々の剤形をとることができ、固体担体を用いる場合は
、錠剤、散剤、−粒剤、硬ゼラチンカプセル剤、全開又
はトローチ剤とすることができる。固体担体の葉は広範
に変えることができるが好ましくは約/■〜約/fとす
る。Various dosage forms can be taken, including tablets, powders, granules, hard gelatin capsules, rolls or lozenges when solid carriers are used. The foliation of the solid support can vary widely, but is preferably from about /■ to about /f.
液状の担体を用いる場合は、シロップ、乳液、軟ゼラチ
ンカプセル、更にアンプル入りのような滅菌注射液又は
水性若しくは非水性の懸濁液とすることができる。If a liquid carrier is used, it can be a syrup, emulsion, soft gelatin capsule, sterile injectable solution such as an ampoule, or an aqueous or non-aqueous suspension.
また、化合物(1)をシクロデキストリン包接体又はす
Iソーム中に入れる等の操作をして、用いることもでき
る。Further, compound (1) can also be used after being incorporated into a cyclodextrin clathrate or an Isome.
本発明の過酸化脂質生成抑制剤は、優れた作用を有し、
諸種虚血性疾患若しくはそれに基づく諸種疾患、即ち、
脳梗塞、脳卒中等の脳血管障害、又はそれらに起因する
脳機能低下、血管性痴呆、加齢に伴う脳血管組織病変等
の諸棟脳挾患、心筋梗禦、心不全等心筋虚血に基づく諸
種心疾患及び諸種末梢循環障害等の予防・治療剤として
有用である。The lipid peroxide production inhibitor of the present invention has excellent effects,
Various ischemic diseases or various diseases based thereon, i.e.,
Based on myocardial ischemia such as cerebrovascular disorders such as cerebral infarction and cerebral apoplexy, or decreased brain function caused by them, vascular dementia, age-related cerebrovascular tissue lesions, myocardial infarction, heart failure, etc. It is useful as a preventive/therapeutic agent for various heart diseases and various peripheral circulation disorders.
以下、実施例によシ本発明を更に具体的に説明するが本
発明はその要旨を越えない限9以下の実施例によって限
定されるものではない。Hereinafter, the present invention will be explained in more detail with reference to examples, but the present invention is not limited to the following nine examples as long as the gist of the present invention is not exceeded.
実施例/
弘−メチル−/−フェニル−3−(3−ピリジル)−2
−ピラゾリン−j−オンの合成λ−ニコチニルプロピオ
ン酸エチル2.02tにフェニルヒドラジン/、OJ’
fを加え?0−タ0℃で30分間奉押した。放冷後、
反応?Jl物をメタノール−クロロホルム混合溶媒より
再結晶して、≠−メチルー/−フェニルー3−(3−ピ
リジル)−一−ピラゾリンー!−オン(化合物扁/)
/、s s fを無色結晶として得た。Example/Hiro-methyl-/-phenyl-3-(3-pyridyl)-2
-Synthesis of pyrazolin-j-one 2.02t of ethyl λ-nicotinylpropionate/phenylhydrazine/, OJ'
Add f? It was pressed at 0°C for 30 minutes. After cooling,
reaction? The Jl product was recrystallized from a methanol-chloroform mixed solvent to obtain ≠-methyl-/-phenyl-3-(3-pyridyl)-1-pyrazoline-! -on (compound flattened/)
/, s s f was obtained as colorless crystals.
収出二67チ
融点=7弘/−/弘2℃
実施例2〜2≦
実施例/と同様にして表/に化合物A 2−2≦として
示す化合物を合成した。Yield: 267° C. Melting point: 7 Hiroshi/−/Hiro2° C. Examples 2-2≦ Compounds shown in Table 2 as Compound A 2-2≦ were synthesized in the same manner as in Example 2.
応用例/
(1)脂質過酸化抑制作用
(a) 脳ホモジニネートの作製
ウィスター(Wistar )系雄性ラットを用い、以
下の操作手順に従って脳ホモジエネート11した。ペン
トノ(ルビタールナトリウム1fjll19/鱈の復腔
内投与で麻酔下に開胸し、左心室からポリエチレンチュ
ーブを大動脈内に挿入し固定した。次いで、このチュー
ブを介して氷冷したj OmMリン酸塩緩衝生理食塩水
(pH7,’fi ) (以下「73日」という。)で
脳潜流を行い、全層を摘出した。小脳を除去後、大脳の
湿重量を測定し、その9倍量のPBSを加え、氷水中に
おいてテフロンホモジエナイザーで破砕し均質化した。Application example/(1) Lipid peroxidation inhibitory effect (a) Preparation of brain homogenate Using male Wistar rats, brain homogenate 11 was prepared according to the following operating procedure. The chest was opened under anesthesia with pentono (rubital sodium 1fjll19/cod) administered intraluminally, and a polyethylene tube was inserted into the aorta from the left ventricle and fixed. Next, ice-cold j OmM phosphate was passed through this tube. Brain infusion was performed with buffered physiological saline (pH 7, 'fi) (hereinafter referred to as "73 days"), and the entire thickness was removed. After removing the cerebellum, the wet weight of the cerebrum was measured, and 9 times the amount of PBS was added. was added and homogenized by crushing with a Teflon homogenizer in ice water.
この脳ホモジエネートを弘℃において22θo rpm
で70分間遠心分離後、上清部0.3mlを共栓付遮光
試験管に分取し、薬物評価用層ホモジエネートとした。This brain homogenate was heated at 22θo rpm at Hiro°C.
After centrifugation for 70 minutes, 0.3 ml of the supernatant was collected into a light-shielding test tube with a stopper and used as a layer homogenate for drug evaluation.
(b) 被験薬の評価
(a)で調製した脳ホモジエネートにPBSo、コ一及
び被験薬のエタノール溶液70μt(0,3〜100μ
Mの公比3での濃度)を添加し、37℃の温浴中で30
分間加温した。(b) Evaluation of the test drug Add 70μt (0.3 to 100μt) of the ethanol solution of PBSo, Co., and test drug to the brain homogenate prepared in (a).
M concentration at a common ratio of 3) was added and the mixture was heated to
Warmed for minutes.
次いで、3!−過塩素酸水溶液200μtを添加後、弘
℃においてコロθOrpmで10分間遠心分離し、上清
を得た。また、ブランク測定用として被験薬のエタノー
ル溶液70μtの代りにエタノール70μtを添加しく
ブランク)、同様に操作した。Next, 3! - After adding 200 µt of perchloric acid aqueous solution, centrifugation was performed for 10 minutes using Colo θOrpm at Hiro°C to obtain a supernatant. In addition, for blank measurement, 70 μt of ethanol was added instead of 70 μt of the ethanol solution of the test drug (blank), and the same operation was performed.
(c)過酸化脂質の定量
(b)で得た上清部θ、/1ttlに2.7%ドデシル
硫酸す) IJウム水溶液0.2 m/、 20 %酢
酸緩衝液(pH3,s ) /、j肩11θ、47%コ
ーチオバルビツール酸水溶液/、5d及び蒸留水0.7
rn/jを加えて混和した。次いで、この混液を沸騰水
浴中で60分間加熱後、氷水で急速に冷却し、蒸留水/
、0rttl及びピリジン−ブタノール混液(/ :
/ ! ) j、0 、/を加え、約30秒間振盪後、
j 000 rpmで70分間遠心分離し、その上清部
を過酸化脂質測足用試料とした。なお、リボパーオキシ
ド−テスト試薬(Lipoperoxtde−test
)(和光紬薬■製; /、/、!、!−テトラエトキ
シプロパンsnm01/m/含有)0./llを(1:
I)で得た脳ホモジエネートの代シに添加し、標準液と
した。(c) Quantification of lipid peroxide 2.7% dodecyl sulfate is added to the supernatant θ obtained in (b)/1 ttl) IJum aqueous solution 0.2 m/20% acetate buffer (pH 3, s)/ , j shoulder 11θ, 47% aqueous solution of corchiobarbituric acid/, 5d and distilled water 0.7
rn/j was added and mixed. This mixture was then heated in a boiling water bath for 60 minutes, rapidly cooled with ice water, and distilled water/distilled water.
, 0rttl and pyridine-butanol mixture (/:
/! ) j, 0, / and after shaking for about 30 seconds,
The mixture was centrifuged at J 000 rpm for 70 minutes, and the supernatant was used as a sample for lipid peroxide foot measurement. In addition, riboperoxide-test reagent (Lipoperoxide-test)
) (manufactured by Wako Tsumugi ■; /, /,!,!-Contains tetraethoxypropane snm01/m/) 0. /ll(1:
It was added to a substitute for the brain homogenate obtained in I) to serve as a standard solution.
過酸化脂質は螢光分光光度計(■日立製作所製2017
型)を用い、励起波長!/!nm。Lipid peroxide was measured using a fluorescence spectrophotometer (■2017 manufactured by Hitachi, Ltd.)
type) and the excitation wavelength! /! nm.
螢光波長! j Onmで測定し、次式に従って過酸化
脂質1(TBA値)を求めた。Fluorescent wavelength! j Onm, and lipid peroxide 1 (TBA value) was determined according to the following formula.
F;標準液の螢光強度
f;被験薬の螢光強度
次いで、(b)のブランクのTBA値に対する被験薬缶
濃度の抑制率を求め、最小二乗法に従ってIC5o値を
算出した。結果を表/に示す。F: Fluorescence intensity of standard solution f: Fluorescence intensity of test drug Next, the inhibition rate of the concentration of the test drug can against the TBA value of the blank in (b) was determined, and the IC5o value was calculated according to the least squares method. The results are shown in Table/.
(2)脳虚血再開通モデルにおける保護作用体重約u0
0fのウィスター(Wistar )系雄性ラットにd
−ツボクラリン0.1〜を筋肉内投与して不動化し、気
管カニユーレ装着後、人工呼吸下に頭部を脳定位固定装
置に保定した。頭皮を切開し、頭蓋骨を穿孔後、硬膜下
圧大脳皮質前頭葉表面上に脳波導出用の電うを存置した
。電極を歯科用セメントを用いて頭蓋骨に固定後、動物
を背位に保持した。次いで、全身圧測定用のカニユーレ
を左大腿動脈内に、d−ツボクラリン追加投与用のカニ
ユーレを左大腿静脈内にそれぞれ留置した。(2) Protective effect in cerebral ischemia recanalization model weight approximately u0
d to 0f Wistar male rats.
- Tubocurarine 0.1~ was administered intramuscularly to immobilize the patient, and after attaching a tracheal cannula, the head was held in a stereotaxic apparatus under artificial respiration. After incising the scalp and drilling a hole in the skull, an electroencephalogram for deriving electroencephalograms was placed on the surface of the frontal lobe of the cerebral cortex under subdural pressure. After fixing the electrode to the skull using dental cement, the animal was held in a dorsal position. Next, a cannula for measuring systemic pressure was placed in the left femoral artery, and a cannula for additional administration of d-tubocurarine was placed in the left femoral vein.
心拍数は動脈波によって心拍数計を駆動し測定記録した
。Heart rate was measured and recorded by driving a heart rate meter using arterial waves.
血圧、心拍数及び脳波の諸パラメーターの安定後に、/
%トラガカントゴム溶液で/ r+!t/辞となるよう
に懸濁調製した本発明の有効成分/ Oq / A9を
脳虚血負荷30分前に十二指腸内に直接投与した。対照
群には、同容量の/チトラガカントゴム溶液のみを同様
に投与した。After stabilization of blood pressure, heart rate, and electroencephalogram parameters, /
% tragacanth gum solution/r+! The active ingredient of the present invention /Oq/A9, which had been suspended to give a concentration of 10%, was directly administered into the duodenum 30 minutes before cerebral ischemic challenge. The control group received the same volume of gum/chitragacanth solution alone.
薬物投与70〜20分後に脳波、血圧及び心拍数を多用
途監視記録装置(日本光電■與、RM−J’ j型)上
で監視しながら、脳虚血負荷のために以下の術式に従っ
て操作を行った。70 to 20 minutes after drug administration, brain waves, blood pressure, and heart rate were monitored on a multipurpose monitoring and recording device (Nihon Kohden ■, RM-J'j model), and cerebral ischemic stress was measured according to the following procedure. performed the operation.
先ず、左肋軟骨端部で肋骨を遊離し、開胸した。次いで
、大動脈起始部で露出した左総頚動脈と左推骨動脈を同
時に、続いて枕頭動脈を、動脈クリップを用いて薬物投
与30分後に閉塞することによって、70分間の頭部血
流の遮断を行った。First, the rib was released at the end of the left costal cartilage, and the chest was opened. Next, the left common carotid artery and left peristaltic artery exposed at the aortic root were simultaneously occluded, followed by the pulvinar artery using an arterial clip 30 minutes after drug administration to block blood flow to the head for 70 minutes. I did it.
頭部血流の再開通は、前記各部位に装着した一本の動脈
クリップを同時に解除することによって行った。Recanalization of blood flow to the head was performed by simultaneously releasing one arterial clip attached to each region.
薬物の脳虚血負荷再開通抜の障害に対する保物作用は、
脳波の回復の有無によって検討した。The protective effect of drugs on the impairment of cerebral ischemic load recanalization is as follows:
The results were evaluated based on the presence or absence of EEG recovery.
なお、実験中は保温マットを用い、動物の@腸温を32
〜3r℃に保持した。また、直III!Vmは脳波、大
腿動脈圧及び心拍数と共にレコーダー上に連続描記した
。During the experiment, a heating mat was used to maintain the animal's intestinal temperature at 32°C.
The temperature was maintained at ~3r°C. Also, Nao III! Vm was continuously recorded on a recorder along with electroencephalogram, femoral artery pressure, and heart rate.
脳虚血を70分間負荷したところ、小面直後から脳波の
常圧は骨下し、約75秒も経過すると脳波は消失、平坦
化した。このような虚血負荷中の脳波の千用化は対照群
及び本発明の有効成分投与群の双方に共通して認められ
た。When cerebral ischemia was applied for 70 minutes, the normal pressure of the electroencephalogram decreased immediately after the facet, and after about 75 seconds, the electroencephalogram disappeared and became flat. Such an increase in brain waves during ischemic stress was observed in both the control group and the group administered with the active ingredient of the present invention.
70分間の脳虚血を解除し、再開通しても、対照群では
金側脳波の出現は全く認められず、虚血負荷中と同様に
平坦化されたままに推移した。このような平坦脳波の持
続によって、動物は再開通後平均25分には死亡した。Even after 70 minutes of cerebral ischemia was released and the brain was recanalized, the appearance of gold-sided electroencephalograms was not observed at all in the control group, and they remained flat as during ischemic stress. Due to the persistence of these flat EEGs, the animals died on average 25 minutes after recanalization.
しかしながら、本発明の有効成分化合物A//投与群で
は、再開通中に脳波が回復出現し、いわゆる脳機能の回
復と共に心脈管系の機能が賦活、正常化された。これら
の総合的な結果として、動物の生存時間は明らかに延長
された。However, in the group administered with the active ingredient compound A// of the present invention, the brain waves recovered during recanalization, and the so-called recovery of brain function and the function of the cardiovascular system were activated and normalized. As a result of these, the survival time of the animals was clearly extended.
応用例2
本発明の過酸化脂質生成抑制剤の製剤化(1)錠剤
下記成分を常法に従って混合し、慣用の装置によシ打錠
した。Application Example 2 Formulation of lipid peroxide production inhibitor of the present invention (1) Tablet The following ingredients were mixed according to a conventional method and tableted using a conventional device.
化合物A/ 10 η結晶セルロー
ス コ/ q
コーンスターチ 33 ■
乳 糖 ご5 ■ス
テアリン酸マグネシウム 7.3η(2)軟カプ
セル剤
下記成分を常法に従って混合し、軟カプセルに充填した
。Compound A/ 10 η Crystalline cellulose / q Cornstarch 33 ■ Lactose 5 ■ Magnesium stearate 7.3η (2) Soft capsules The following ingredients were mixed according to a conventional method and filled into soft capsules.
化合物A / / 0 ηオリーブ
油 10!mq
レシチン t、smq(3)注射用
製剤
下記成分を常法に従って混合して/ Wlアンプルを調
製した。Compound A / / 0 η Olive oil 10! mq lecithin t, smq (3) Injection preparation The following ingredients were mixed according to a conventional method to prepare a /Wl ampoule.
化合物A/ o、77nq塩化ナト
リウム 3.j胃注射用蒸留水
/、θme手続補正書(自発)
昭和62年/ユ月X日
1 事件の表示 昭和A/年 特 許 願第27736
≠号2 発 明 の名称
ピラゾロン誘導体
3 補正をする者Compound A/o, 77 nq Sodium Chloride 3. j Distilled water for gastric injection
/, θme procedural amendment (spontaneous) 1986/U month X day 1 Case description Showa A/Year Patent Application No. 27736
≠No. 2 Name of the invention Pyrazolone derivative 3 Person making the amendment
Claims (1)
化学式、表等があります▼・・・(1) (式中、R^1はシクロアルキル基、置換基を有してい
てもよいフェニル基またはピリジル基を表わし、R^2
は水素原子またはアルキル基を表わし、R^3はピリジ
ル基、イミダゾリル基またはフラニル基を表わし、nは
0または1を表わす。但し、nが0でR^3がピリジル
基のとき、R^2はアルキル基を表わし、nが0でR^
3がフラニル基のとき、R^1は置換フェニル基を表わ
す。)で表わされるピラゾロン誘導体。(1) General formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ and/or ▲Mathematical formulas,
There are chemical formulas, tables, etc.▼...(1) (In the formula, R^1 represents a cycloalkyl group, a phenyl group or a pyridyl group that may have a substituent, and R^2
represents a hydrogen atom or an alkyl group, R^3 represents a pyridyl group, an imidazolyl group or a furanyl group, and n represents 0 or 1. However, when n is 0 and R^3 is a pyridyl group, R^2 represents an alkyl group, and when n is 0, R^3 is a pyridyl group.
When 3 is a furanyl group, R^1 represents a substituted phenyl group. ) pyrazolone derivatives.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27736486A JPS63130593A (en) | 1986-11-20 | 1986-11-20 | Pyrazolone derivative |
US07/123,237 US4906644A (en) | 1986-11-20 | 1987-11-20 | Lipid-peroxide formation inhibiting composition and novel compounds useful therefor |
DE3789754T DE3789754T2 (en) | 1986-11-20 | 1987-11-20 | The formation of lipid-peroxide-inhibiting composition and suitable compounds. |
EP87117175A EP0269030B1 (en) | 1986-11-20 | 1987-11-20 | Lipid-peroxide formation inhibiting composition and novel compounds useful therefor |
US07/451,526 US4990619A (en) | 1986-11-20 | 1989-12-18 | Pyrazoline derivatives |
US07/606,829 US5089515A (en) | 1986-11-20 | 1990-10-31 | Lipid-peroxide formation inhibiting composition and novel compounds useful therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27736486A JPS63130593A (en) | 1986-11-20 | 1986-11-20 | Pyrazolone derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63130593A true JPS63130593A (en) | 1988-06-02 |
Family
ID=17582495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP27736486A Pending JPS63130593A (en) | 1986-11-20 | 1986-11-20 | Pyrazolone derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63130593A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010507606A (en) * | 2006-10-26 | 2010-03-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Substituted dihydropyrazolones and their use as HIF-prolyl-4-hydroxylase inhibitors |
-
1986
- 1986-11-20 JP JP27736486A patent/JPS63130593A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010507606A (en) * | 2006-10-26 | 2010-03-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Substituted dihydropyrazolones and their use as HIF-prolyl-4-hydroxylase inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4316794B2 (en) | Isoquinoline derivatives and pharmaceuticals | |
SU1486060A3 (en) | Method of producing derivatives of 2-indolinone | |
JPS61263917A (en) | Cerebral function normalizing agent | |
TW201240662A (en) | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases | |
KR19990072616A (en) | Method of treating heart failure | |
WO2024060912A1 (en) | 2h-benzotriazole derivative, preparation method therefor, and pharmaceutical composition containing same | |
WO2006035617A1 (en) | α2 RECEPTOR BLOCKING AGENT CONTAINING INDOLE DERIVATIVE AS ACTIVE INGREDIENT AND VASODILATOR | |
BR112016005606B1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND USES OF A COMPOUND | |
JP3165935B2 (en) | 3 (2H) -pyridazinone derivative, method for producing the same, and pharmaceutical composition containing the same | |
JPH0535128B2 (en) | ||
HU202106B (en) | Process for producing pharmaceutical compositions containing pyrazolin derivatives | |
EP0269030B1 (en) | Lipid-peroxide formation inhibiting composition and novel compounds useful therefor | |
JPS63130593A (en) | Pyrazolone derivative | |
JP2017513934A5 (en) | ||
JPS6258336B2 (en) | ||
JPS63130592A (en) | Agent for suppressing formation of lipid peroxide | |
JP2811577B2 (en) | Cardiac alkanoyl and aroyloxazolones | |
TW322473B (en) | ||
US6071968A (en) | Phenylenediamine derivative radical scavenger, brain-infarction depressant, and brain-edema depressant | |
WO1994014769A1 (en) | N-substituted indole derivative | |
JPS63307877A (en) | Cardiac stimulant tricyclic imidazolones | |
HU176300B (en) | Process for producing 3-phenoxypyridine-monosulfate | |
WO2024099430A1 (en) | Pharmaceutical composition comprising aak1 inhibitor | |
JPS6348273A (en) | Quinolone cardiac | |
JP2007530424A (en) | Novel N-hydroxy-4- (3-phenyl-5-methyl-isoxazole-4-yl) -benzenesulfonamide solvate |